The DOI matches its Crossref record; the references it cites are not checked yet.
Peptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively
Abstract
Peptide YY (PYY) and glucagon like peptide (GLP)-1 are cosecreted from intestinal L cells, and plasma levels of both hormones rise after a meal. Peripheral administration of PYY3–36 and GLP-17–36 inhibit food intake when administered alone. However, their combined effects on appetite are unknown. We studied the effects of peripheral coadministration of PYY3–36 with GLP-17–36 in rodents and man. Whereas high-dose PYY3–36 (100 nmol/kg) and high-dose GLP-17–36 (100 nmol/kg) inhibited feeding individually, their combination led to significantly greater feeding inhibition. Additive inhibition of feeding was also observed in the genetic obese models, ob/ob and db/db mice. At low doses of PYY3–36 (1 nmol/kg) and GLP-17–36 (10 nmol/kg), which alone had no effect on food intake, coadministration led to significant reduction in food intake. To investigate potential mechanisms, c-fos immunoreactivity was quantified in the hypothalamus and brain stem. In the hypothalamic arcuate nucleus, no changes were observed after low-dose PYY3–36 or GLP-17–36 individually, but there were significantly more fos-positive neurons after coadministration. In contrast, there was no evidence of additive fos-stimulation in the brain stem. Finally, we coadministered PYY3–36 and GLP-17–36 in man. Ten lean fasted volunteers received 120-min infusions of saline, GLP-17–36 (0.4 pmol/kg·min), PYY3–36 (0.4 pmol/kg·min), and PYY3–36 (0.4 pmol/kg·min) + GLP-17–36 (0.4 pmol/kg·min) on four separate days. Energy intake from a buffet meal after combined PYY3–36 + GLP-17–36 treatment was reduced by 27% and was significantly lower than that after either treatment alone. Thus, PYY3–36 and GLP-17–36, cosecreted after a meal, may inhibit food intake additively.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Y2R receptor is present in the brain and its agonism results in a reduction in food intake and increased satiety [91].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [91]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 34 · Cited by 371
Metadata
- Authors
- Neary, N. M., Small, C. J., Druce, M. R., Park, A. J., Ellis, S. M., Semjonous, N. M., Dakin, C. L., Filipsson, K., Wang, F., Kent, A. S., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Bloom, Stephen R.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2005-12-01
- Volume
- 146
- Issue
- 12
- Pages
- 5120-5127
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2096780893
- Cited by
- 371
- References
- 34
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 12 · 2023: 12 · 2022: 8 · 2021: 21 · 2020: 10 · 2019: 18 · 2018: 11 · 2017: 17 · 2016: 9 · 2015: 24 · 2014: 41 · 2013: 24 · 2012: 25
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- PYY3-36, feeding inhibition, appetite regulation, additive effects, gastrointestinal hormones, intestinal L cells, c-Fos immunoreactivity, hypothalamus, arcuate nucleus, brainstem, ob/ob mice, db/db mice, obesity, energy intake, satiety hormones
- MeSH terms
- Animals, Behavior, Animal, Energy Intake, Diabetes Mellitus, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Drug Synergism, Eating, Glucagon-Like Peptides, Feeding Behavior, Female, Glucagon, Humans, Immunohistochemistry, Injections, Intraperitoneal, Male, Mice, Inbred C57BL, Motor Activity, Obesity, Peptide Fragments, Peptide YY, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively. https://app.cochat.ai/papers/10.1210/en.2005-0237
- The paper
- Neary, N. M., Small, C. J., Druce, M. R., Park, A. J., Ellis, S. M., Semjonous, N. M., Dakin, C. L., Filipsson, K., Wang, F., Kent, A. S., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2005). Peptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively. Endocrinology. https://doi.org/10.1210/en.2005-0237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.